A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Levodopa (Primary) ; Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 22 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.